Summary of CPACS potential opportunity, the proposed P1/P2 allcomers trial is focused on Doxorubicin basket trial for CPACS/FTO.
The Triangle report, places sales for US (only) Doxorubicin - Breast Cancer treatments at $1.7b USD p.a. It doesn't consider all indications and global sales / CPACS / FTO, which is where this gets farfetched if you extrapolate sales potential for other indications.
The following are implied opportunities from research reports, historical clinical trials, various assumptions so not to be relied on DYOR not advice. Props to @johndprent (Post #: 73756269) and @Mason14 (Post #: 73390872) I can't take credit for the summary.
Source: Triangle Report (app.sharelinktechnologies.com/announcement/asx/e0c332e661c11f781398af97fd2fe108)
General Comments / Chat, page-10906
-
- There are more pages in this discussion • 470 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
-0.030(1.75%) |
Mkt cap ! $286.2M |
Open | High | Low | Value | Volume |
$1.73 | $1.73 | $1.68 | $119.9K | 70.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3012 | $1.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 6382 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3012 | 1.660 |
1 | 1205 | 1.650 |
1 | 3067 | 1.630 |
1 | 615 | 1.620 |
2 | 18200 | 1.615 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 6382 | 1 |
1.735 | 609 | 1 |
1.750 | 10096 | 2 |
1.780 | 4483 | 1 |
1.790 | 1000 | 1 |
Last trade - 15.07pm 03/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |